Mechanistic approaches through nanocarriers in leukemia: a review

Abstract

Leukemia is a global concern as it is affecting the global population. Many anticancer drugs have used in the disease, although toxicities can not ignored. The important targets for the disease are B cell receptor pathway that is  spleen tyrosine kinase, mammalian target of rapamycin (mTOR), phosphoinositide 3’-kinase (PI3K), Bruton's tyrosine kinase (BTK) which potentially the disease and can be used as the target for targeted delivery of anticancer drugs in disease. The need of the hour is to develop the formulation, should be specific and have minimum toxicities. The nanoformulations have proved their efficacy in disease targeting and minimization of toxicities. In this review paper, we have performed a systematic review of more than 250 papers and selected those one related to our research work. The findings suggest that nanoparticles can be a game changer in the lane of disease management as they can be  targeted delivery and minimization of toxicities too.